Literature DB >> 6982759

Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex.

E L Reinherz, S Meuer, K A Fitzgerald, R E Hussey, H Levine, S F Schlossman.   

Abstract

Four distinct surface molecules on human T cells are defined by the monoclonal antibodies anti-T1, anti-T3 (anti-T3A), anti-T11 and anti-T12. Following cell binding, anti-T3 (anti-T3A) and anti-T1 induce independent modulation of their respective ligands, whereas anti-T11 and anti-T12 do not. To explore the biological consequences of this modulation, we used cloned populations of T4 and T8 cytotoxic T lymphocytes. Anti-T3 (anti-T3A), but not anti-T1, inhibits cytotoxic T lymphocyte effector function by T4 and T8 clones as well as antigen-specific T cell recognition. The latter is not secondary to a generalized inhibitory effect since responsiveness to interleukin 2 is maintained. Moreover, after modulation, cytotoxic T lymphocytes recover cytolytic function in parallel with reexpression of surface T3 molecules. We provide evidence for a direct linkage between antigen recognition by T lymphocytes and surface expression of the T3 molecular complex.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6982759     DOI: 10.1016/0092-8674(82)90278-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  112 in total

1.  Defective signal transduction by the CD2 molecule in immature T-cell receptor/CD3- thymocytes.

Authors:  L A Turka; M C Fletcher; N Craighead; C B Thompson; C H June
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

2.  Flow cytometry resonance energy transfer suggests an association between low-affinity interleukin 2 binding sites and HLA class I molecules.

Authors:  A Harel-Bellan; P Krief; L Rimsky; W L Farrar; Z Mishal
Journal:  Biochem J       Date:  1990-05-15       Impact factor: 3.857

3.  Selective inhibition of interleukin 2 gene function following thymocyte antigen/major histocompatibility complex receptor crosslinking: possible thymic selection mechanism.

Authors:  D Ramarli; D A Fox; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

4.  Regulation of the in vitro monoclonal immunoglobulin production in cultures of peripheral blood mononuclear cells and bone marrow cells from myeloma patients mediated by T cell dependent mitogens.

Authors:  D Peest; S Gasch; C Thiele; B Bartels; U Brunkhorst; I Dallmann; M Hoffmann; I Schedel; H Deicher
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

5.  Human thymocytes bind to autologous and allogeneic thymic epithelial cells in vitro.

Authors:  K H Singer; L S Wolf; D F Lobach; S M Denning; D T Tuck; A L Robertson; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

Review 6.  The role of OKT3 in clinical transplantation.

Authors:  D J Norman; M R Leone
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

7.  Discordance between surface and cytoplasmic expression of the Leu-4 (T3) antigen in thymocytes and in blast cells from childhood T lymphoblastic malignancies.

Authors:  M P Link; S J Stewart; R A Warnke; R Levy
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

Review 8.  The human T-cell receptor.

Authors:  O Acuto; M Fabbi; A Bensussan; C Milanese; T J Campen; H D Royer; E L Reinherz
Journal:  J Clin Immunol       Date:  1985-05       Impact factor: 8.317

9.  Downregulation of T cell receptor expression by CD8(+) lymphocytes in kidney allografts.

Authors:  R B Mannon; B L Kotzin; C Nataraj; K Ferri; E Roper; R J Kurlander; T M Coffman
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

10.  Antigenic stimulation regulates the level of expression of interleukin 2 receptor on human T cells.

Authors:  M E Hemler; M B Brenner; J M McLean; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.